KO Client VitriVax Closes Series A Financing Round

VitriVax, the developer of a novel stabilization and delivery platform for vaccines and therapeutics, has closed its first institutional financing round with Adjuvant Capital.

KO partners Jon Taylor and Brad Schoenfeld, and attorney Matt Burns represented VitriVax in the financing round.

The Series A proceeds will be used to develop and commercialize a technology with the potential to eliminate barriers to global vaccine administration, extending their life-saving benefits to underserved populations and compressing multi dose regimens into a single shot, according to a press release.

“We could not be happier to partner with Adjuvant Capital as our lead investor to help us maximize the impact of VitriVax and our game-changing ALTA™ formulation platform,” VitriVax CEO Matt Raider said in the press release.

“Building on the early development of our technology at CU Boulder, with support from the Bill & Melinda Gates Foundation, we are excited to work alongside Adjuvant and its partners to further advance the platform and enable new and improved vaccines and therapeutics for high-value public health challenges.”

Read more about the financing.